CSPC Baike Biopharmaceutical

CSPC Baike Biopharmaceutical, a key subsidiary of CSPC Pharmaceutical Group, is a leading Chinese biopharmaceutical company specializing in the development and commercialization of recombinant protein drugs. The company is best known for its flagship product, Jinyouli (Pegfilgrastim), which was the first long-acting granulocyte colony-stimulating factor (G-CSF) approved in China to prevent chemotherapy-induced neutropenia. CSPC Baike operates advanced R&D and manufacturing facilities in Yantai, focusing on therapeutic areas such as oncology, metabolic disorders, and bone health. Leveraging its proprietary PEGylation technology platform, the company maintains a robust pipeline of biologics, including long-acting insulin and monoclonal antibodies. The company plays a critical role in the parent group's strategic shift toward high-value innovative biologics.